1 / 37

Immunological aspects of transplantation and pregnancy

Immunological aspects of transplantation and pregnancy. Immunologically „non-self” cells/tissues. Tumors. Transplanted tissues. Embryo. B rief history of transplants. 1933 : First human-to-human kidney transplant (kidney never functioned).

bcitizen
Download Presentation

Immunological aspects of transplantation and pregnancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Immunological aspects of transplantation and pregnancy

  2. Immunologically „non-self” cells/tissues Tumors Transplanted tissues Embryo

  3. Brief history of transplants • 1933: First human-to-human kidney transplant (kidney never functioned). • 1954: First successful kidney transplant from one twin to another with no anti-rejection drugs necessary. • 1967: First successful liver transplant. • 1967: World's first heart transplant. • 1978: Uniform Brain Death Act passed - "Brain death" IS death. • 1983: Cyclosporine, a revolutionary anti-rejection drug, approved for commercial use, sparking a huge increase in transplants.

  4. Transplantation • Self • Non-self • Transplantation - immunological tolerance to non-self (cell, tissue, organ) • Main factors: • T and B lymphocytes • genetic polymorphism of MHC glycoproteins

  5. Types of Transplantation • natural - pregnancy • arteficial - therapic transplantation (including transfusion of blood !) • ortotopic - the graft transplanted to identical locus • heterotopic - transplantation to non- identical parts of the body

  6. Types of Transplantation • Autograft: Transplant from one area to another on the same individual - no immune response. • Isograft/Syngraft: Transplant from one individual to another genetically identical – no immune response. • Xenograft: Transplant from donor to a recipient of a differet species - immune response, the transplant may berejected. • Allograft: Transplant from one individual to a genetically dissimilar(allogenic) individual of the same species - immune respons, rejection (the most common)

  7. Significant Transplantation Antigens • MHCs - Mendelian, codominant inh. • MHC I. - expressed on each nuclear cell - infection with viruses or tumors can result the total loss of MHC I. • MHC II. - expressed on APC-s - cytokines or inflammation can induce their expression on other cells • Minor MHC-s

  8. Human Leukocyte Antigen - HLA • Coded on Chr. 6p • Polymorphism: DRb B DPb A C DQb DQa DPa DRa MHC I. MHC II.

  9. Minor-H Antigens • Any polymorph peptide presented on the graft • They are bound to MHC I. • They can not induce synthesis of antibodies BUT • They are recognized by Tc lymphocytes • Their diversity can enhance the intensity of immune reactions in the case of MHC divergence • They can induce rejection also in the case of total MHC identity

  10. enzyme Blood-Groups • Alloantigens of RBCs • AB0 - coded on the Chr.9 • a glycosphingolipid is coded by the dominant H-gene (this is independent from the AB0 !) • enzymes - expressed differently in A or B allels - are responsible for differences • these enzymes can modify with an N-acethyl-galactiseamine or galactose the lipid The antigens are present on bacteria of intestine, therefore immunity develops towards the non-self antigens, while the selfs are tolerated

  11. Rh-antigens • Responsible genes are on Chr. 1 • Antigens: D, d, C, c, E, e • The antigens are expressed ONLY on RBCs • Immuneresponse (IgG) is a result of alloimmunizations - e.g. transfusion or pregnancy

  12. 1st pregnancy Rh-incompatibility Rh- cell (mother) Rh+ cell Rh specific B cell memory B cell (in mother) 2nd pregnancy memory B cell plasma cell + anti Rh IgG

  13. Recognition of alloantigens • Th Ly cells - release of cytokines • Tc Ly cells - effector functions, inflammation • NK Ly cells - “ “

  14. Alloantigen-presentation Direct presentation Indirect presentation Recipient T Ly Recipient T Ly Donor APS Recipient APS Donor MHC + donor/recipient peptide Recipient MHC + donor peptide

  15. Criteria of Donor-selection • Main criteria - the identity of HLA antigens • Living persons - time is given for identification of all HLA markers • Identical twins > sisters or brothers (25% identity of haplotypes) > parents > other relative • Cadaver - the time is limited; AB0, RhD, HLA-A, -B, -DR are tested • More criteria: to belong the same population; to find a genetically close donor - network of transpl. centr.

  16. Xenogene transplantation • interspecies transplantation • apes and swine - kidney, heart BUT • hyperacute rejections - IgM -Gala1-3Gal • NK Ly and monocytes attracted by endothel • expr. of adhesion molecules induced by chemokines MORE problem: the interspecies transfer of retroviruses

  17. Pretreatment of recipient and the graft • Prior immunization of the recipient ? • Exemption of graft from T Ly and APC-s (perfusion of vascular syst of the graft -heart or kidney- removes the passanger leukocytes; UV irradiation - inhibits APCs) • Immunosuppressive therapy - before and after TP Problem: these patients are highly sensible to pathogens and tumors

  18. Transplantation of Bone-marrow • hemopoetic stem cells are introduced into the peripherial blood • high ratio of adhered cells - high number of colonies - differentiation • the age of recipient and donor is significant • some cells of adult are not repleaced by TP e.g. gd TCR or B1 Ly are available from umbilical cord or embryonic liver • results a chimera: APCs - recipient T Ly - donor

  19. Graft versus Host reaction (GVH) • special problem of bone-marrow transplantation • intensity depends on the number of T Ly • skin, liver, stomach and intestine are affected • acute GVH: chr. inflammation - Th1 activation, IFNg and TNF • chronic GVH: Th2, autoimmune Prevention: removal of mature T Ly from the bone-marrow, BUT this might decrease the ability of adherence

  20. ?

  21. Transplant Rejection • The immune system recogizes the transplantas foreign and respondsagainst it. • Rejection of transplanted tissue is mediated by T cells. • Rejection occurs in xenografts and allografts. • There are three clinical characteristics of allograft rejection:

  22. Hyperacute rejection: • Destruction of transplant by preformed antibodiessynthesized as a result of previous transplantation. • This type of rejectionoccurs within a few minutes or hours of transplantation.

  23. Chronic rejection: • Transplant destruction caused by cell mediated immunityand antibodies. • This type of rejection occurs months after transplant hasassumed normal function and may result in a complete failure of transplant.

  24. Acute rejection: • Destruction of transplant caused by cell-mediated immunityin recipients not previously sensitized to transplant. • This type of rejectionbegins a few days after transplantation and may result in a complete loss oftransplant function. • It is manifested by infiltration of lymphocytes and macrophages at the rejection site. • Acute rejetion may be reduced byimmuosuppresive therapy.

  25. Factors determining the rate of rejection • Type of transplanted tissue • The site of transplantation • Recipient's circulation • Lymphatic drainage • Expression of stong antigen on graft

  26. MHC and rejection • MHC I antigens are targets for recipient CD8+ T cells inrejection. • Donor MHC II molecules are present on specialized cells in atransplant. • MHC II antigens are targets for recipient CD4+ T cells inrejection. • MHC II molecules are most effective at generating an immuneresponse.

  27. Prolongation of Transplants= Clinical Immunosuppression • Involves a non-specific suppression of bothcell-mediated and humoral immunity. • Focuses on lymphocytic interaction andproliferation, and lymphocytedepletion.

  28. . Antiproliferative agents:antimetabolites, alkylating agents,cyclosporine, FK506, antibiotics Lymphocyte depletion agents: cytotoxic, blocking agents,anti-inflammatory agents

  29. Cyclosporine • the most common immunosuppressive drug • a cyclicmetabolic peptide • inhibits Tcell-receptor-mediated activation events • interferes withcytokine gene transcriptionin T cells • suppressing the production ofinterleukins, IL-1, IL-2,IL-3, IL-4 and IFN-gamma. • the most effective administered prior to transplantation. • Problems:nephrotoxicity, hypertension, B cell lymphoma, increased hair growth on the face • and body.

  30. Cytotoxic and Blocking Agents • Antilyphocyte serum (ALS) or antilymphocyte globulins(ALG), and monoclonal antibodies such as OKT3. • ALS or ALG is producedwhen lymphocytes are injected into animals of different species (rabbit, horse) Directedspecifically against lymphocytes. • OKT3 is a monoclonal antibody to CD3 ofthe TcR. These block recognition of MHC I and II antigens on atransplant.

  31. Anti-inflammatory Agents • Common anti-inflammatory agents include corticosteroids, (prednisone,prednisolone, and methyl prednisolone). • These anti-inflammatory agentsinhibit cytokine synthesis of IL-2, IL-6, and INF-gamma. • They prevent therelease of harmful lysosomal enzymes and induce lysis of lymphocytes. • They also reduce phagocytosis and killing by neutrophilsand macrophages, as well as MHC II expression.

  32. Effects of Immunosuppressive Therapy Cancer: • Nonmelanotic skinand lip cancer (39%) • Lyphoproliferativedisorders (LPD) (14%) • Cervical cancer (8.6%)

  33. Infection • Risk is influenced by the type of trasplant, exposure to potentialpathogens, dose, duration and temporal sequence of immunosuppressivetherapy. • Infection accounts for 40% of all deaths among transplant patients.

  34. Pregnancy The embryo is considered as an allograft which is tolerated by the maternal immune system - even in consecutive pregnancies.

  35. Immunological backgrounds of tolerance in pregnancy • trophoblast cell do not express MHC I and II. or costimulatory molecules • trophoblast are not targets of Tc Ly and not APCs of Th Ly • HLA-G gene codes an MHC I.-like protein: they can mask the placenta to T Ly and inhibit NK Ly by their MHC character • trophoblast leukocyte crossreactive antigen (TLX) inhibits C3b deposition on trophoblast

  36. Immunosuppressive hormones of pregnancy • progesterone, estrogen • corticosteroids • AFP

  37. week 6 - complement proteins - thymus • week 11 - IgM production of B Ly • week 12-13 - mitogen response - GVH reactions BUTthe immunity is provided by the maternal IgG (after birth colostrum provides IgA, phagocytes, lymphocytes and bactericide enzymes for 6 months)

More Related